Clinical Trial

LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated January 26, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
To investigate the activating effect of local lesion low-dose radiotherapy (2Gy) on the tumor immune microenvironment, and the efficacy, safety, and feasibility of its combination with pembrolizumab and standard therapy in patients with advanced pancreatic cancer. Concurrently, to preliminarily establish an efficacy prediction model for the early identification of patient populations who would benefit from the treatment, thereby providing a theoretical foundation for the implementation of precision medicine.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-17.
Trial Details
NCT Number NCT07312422
Lead Sponsor Zhejiang Provincial People's Hospital
Conditions Pancreatic Cancer, PD-L1, PD-1 Inhibitor, LDRT, Proterizumab
Enrollment 10 participants
Start Date 2025-09-30
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-26